Exposure to nonsteroidal anti-inflammatory drugs among older adult patients hospitalized for peptic ulcer disease in Argentina: A case-control study

American Journal Geriatric Pharmacotherapy

Volumn 4, Issue 3, 2006, Pages 251-259

  Insúa, Jorge ^a   Mavros, Panagiotis ^b   Hunsche, Elke ^b   Kong, Sheldon ^b   Tibaudin Agver, Osvaldo ^c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Merck Sharp and Dohme Argentina Inc   (Argentina)

Author keywords

Argentina; NSAID use; peptic ulcer disease; ulcer complications

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTIDIABETIC AGENT; ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DICLOFENAC; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GOLD DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; MELOXICAM; METHOTREXATE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROTON PUMP INHIBITOR; STEROID; SUCRALFATE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; ACUTE ABDOMEN; ADULT; AGED; ANEMIA; ARGENTINA; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DUODENITIS; DUODENUM BLEEDING; DUODENUM PERFORATION; DUODENUM ULCER; FEMALE; GASTRIC ULCER BLEEDING; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HEMATEMESIS; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MELENA; PEPTIC ULCER; PRIORITY JOURNAL; RISK ASSESSMENT; SHOCK; STOMACH EROSION; STOMACH ULCER; VOMITING;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARGENTINA; CASE-CONTROL STUDIES; CHRONIC DISEASE; COMORBIDITY; DRUG UTILIZATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; RISK;

EID: 33751064655     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2006.09.008     Document Type: Article

References (42)

1. Straus W.L., and Ofinan J.J. Gastrointestinal toxicity associated with nonsteroidal anti-inflammatory drugs. Epidemiologic and economic issues. Gastroenterol Clin Nortb Am 30 (2001) 895-920
2. Ofman J.J., MacLean C.H., Straus W.L., et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 29 (2002) 804-812
3. [published correction appears in Lancet 1994;343:1302]. Langman M.J., Weil J., Wainwright P., et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 1075-1078
4. Smalley W.E., and Griffin M.R. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am. 25 (1996) 373-396
5. Kurata J.H., and Nogawa A.N. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol. 24 (1997) 2-17
6. Griffin M.R., Piper J.M., Daugherty J.R., et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 114 (1991) 257-263
7. Hallas J., Lauritsen J., Villadsen H.D., and Gram L.E. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol. 30 (1995) 438-444
8. Visser L.E., Graatsma H.H., and Stricker B.H. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease. Br J Clin Pbarmacol. 53 (2002) 183-188
9. Borum M.L. Peptic-ulcer disease in the elderly. Clin Geriatr Med. 15 (1999) 457-471
10. Smalley W.E., Ray W.A., Daugherty J.R., and Griffin M.R. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 141 (1995) 539-545
11. Chan H.L., Wu J.C., Chan F.K., et al. Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. Gastrointest Endosc. 53 (2001) 438-442
12. Hernandez-Diaz S., and Rodriguez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med. 160 (2000) 2093-2099
13. Weil J., Langman M.J., Wainwright P., et al. Peptic ulcer bleeding: Accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 46 (2000) 27-31
14. Huang J.Q., Sridhar S., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 359 (2002) 14-22
15. International Statistical Classification of Diseases, I0tb Revision Volume I (1992), World Health Organization, Geneva, Switzerland
16. de Jong J.C., van den Berg P.B., Tobi H., and de Jong-van den Berg L.T. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 55 (2003) 591-595
17. Dalton S.O., Johansen C., Mellemkjaer L., et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort study. Arcb Intern Med. 163 (2003) 59-64
18. Stack W.A., Atherton J.C., Hawkey G.M., et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther. 16 (2002) 497-506
19. Bloom B.S. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med. 149 (1989) 1019-1022
20. Beardon P.H., Brown S.V., and McDevitt D.G. Gastrointestinal events in patients prescribed non-steroidal antiinflammatory drugs: A controlled study using record linkage in Tayside. QJ Med. 71 (1989) 497-505
21. MacDonald T.M., Morant S.V., Robinson G.C., et al. Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure: Cohort study. BMJ 315 (1997) 1333-1337
22. Palloni A., Pinto-Aguirre G., and Pelaez M. Demographic and health conditions of ageing in Latin America and the Caribbean. Int J Epidemiol. 31 (2002) 762-771
23. Badley E.M., and Crotty M. An international comparison of the estimated effect of the aging of the population on the major cause of disablement, musculoskeletal disorders. J Rheumatol. 22 (1995) 1934-1940
24. Lanza F.L., and Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and pre vention of NSAID-induced ulcers. Am J Gastroenterol. 93 (1998) 2037-2046
25. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update. Arthritis Rheum. 43 (2000) 1905-1915
26. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120 (2001) 594-606
27. Schnitzer T.J., Kong S.X., Mavros P.P., et al. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: Analysis of a large United States claims database. Clin Ther. 23 (2001) 1984-1998
28. Smalley W., Stein C.M., Arbogast P.G., et al. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum. 46 (2002) 2195-2200
29. van Dijk K.N., ter Huurne K., de Vries C.S., et al. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci. 24 (2002) 100-103
30. Sturkenboom M.C., Burke T.A., Dieleman J.P., et al. Undermilization of preventive strategies in patients receiving NSAIDs. Rheurnatology (Oxford) 42 Suppl 3 (2003) 23-31
31. Rostom A., Wells G., Tugwell P., et al. The prevention of chronic NSAID induced upper gastrointestinal toxicity: A Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol. 27 (2000) 2203-2214
32. Bombardier C., Laine L., Reicin A., et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheuma toid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
33. Laine L., Connors L.G., Reicin A., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124 (2003) 288-292
34. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
35. Langman M.J., Jensen D.M., Watson D.J., et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282 (1999) 1929-1933
36. Watson D.J., Harper S.E., Zhao P.L., et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 160 (2000) 2998-3003
37. Goldstein J.L., Silverstein F.E., Agrawal N.M., et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 95 (2000) 1681-1690
38. Available at:[eh][ir]http://www.fda.gov/cder/drug/infopage/ COX2/NSAIDdecisionMemo.pdf. Accessed. Jenkins J.K., and Seligman P.J. FDA Memorandum. Analysis and recommendations for agency action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk (September 30, 2005)
39. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 344 (2001) 967-973
40. Ko C.W., and Deyo R.A. Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory druginduced peptic ulcer disease. J Gen Intern Med. 15 (2000) 400-410
41. Blower A.L., Brooks A., Fenn G.C., et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharrnacol Ther. 11 (1997) 283-291
42. Iezzoni L.I. Dimensions of risk. In: Iezzoni L. (Ed). Risk Adjustment for Measuring Healtb Outcomes. 2nd ed. (1997), Health Administration Press, Chicago, Ill 43-168